Dual epithelial and stromal targeting in breast cancer using the phase II ROCK2 inhibitor KD025 guided by intravital imaging technology
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210104
- Recipient
-
University Of New South Wales UEI QHAHG1WUM3J1
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $555,506
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Australia
Award details come from USAspending.gov.
About this award
The University of New South Wales received a $555,506.43 three-year Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund a study titled "DUAL EPITHELIAL AND STROMAL TARGETING IN BREAST CANCER USING THE PHASE II ROCK2 INHIBITOR KD025 GUIDED BY INTRAVITAL IMAGING TECHNOLOGY" from March 1, 2022 to February 28, 2025. Through this award, the University will conduct research into investigating medical solutions for breast cancer using a Phase II ROCK2 inhibitor drug and intravital imaging technology. The overarching goal of the Military Medical Research and Development program is to transform military and public health through innovative medical research.
Quick answers
Who received award W81XWH2210104?
W81XWH2210104 was awarded to University Of New South Wales by Medical Command (Department of the Army) on March 1, 2022.
How much is award W81XWH2210104 worth?
$555,506 has been obligated on W81XWH2210104.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award